Adicet Bio (ACET) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, with voting available online or virtually.
Shareholders are encouraged to review proxy materials and vote by June 16, 2026.
Voting matters and shareholder proposals
Election of three class II directors for a three-year term ending at the 2029 annual meeting.
Advisory vote to ratify executive compensation for named executive officers.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Nominees for director positions include Jeffrey Chodakewitz, M.D., Steve Dubin, J.D., and Michael Grissinger.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Adicet Bio
- Major data readouts in LN/SLE and new pipeline updates signal pivotal progress for off-the-shelf cell therapies.ACET
Canaccord Genuity's 46th Annual Growth Conference - Prula-cel enables steroid-free remissions in autoimmune disease; ADI-212 advances in prostate cancer.ACET
Investor presentation - Q2 2026 net loss was $21.4M; cash runway and key clinical milestones extend into H2 2027.ACET
Q2 2026 - All proposals, including director elections and auditor ratification, were approved by stockholders.ACET
AGM 2026 - Major mid-year data update for prula-cel in autoimmune diseases and new solid tumor program advancing.ACET
Jefferies Global Healthcare Conference 2026 - Prula-cel delivers durable remission and immune reset in autoimmune disease, while ADI-212 advances for mCRPC.ACET
Investor presentation - Net loss narrowed, cash runway extends into H2 2027 as pivotal trials advance and risks persist.ACET
Q1 2026 - Virtual annual meeting to elect directors, approve pay, and ratify auditor, with robust governance.ACET
Proxy filing - Prula-cel delivers steroid-free remissions and immune reset in autoimmune disease patients.ACET
Investor presentation